EP299/#232 Genomic instability as a determinant of immune escape in ovarian cancer. (4th December 2022)
- Record Type:
- Journal Article
- Title:
- EP299/#232 Genomic instability as a determinant of immune escape in ovarian cancer. (4th December 2022)
- Main Title:
- EP299/#232 Genomic instability as a determinant of immune escape in ovarian cancer
- Authors:
- Vazquez-Garcia, Ignacio
Uhlitz, Florian
Ceglia, Nicholas
Lim, Jamie
Wu, Michelle
Mohibullah, Neeman
Niyazov, Juliana
Ruiz, Arvin Eric
Soslow, Robert
Ellenson, Lora
Abu-Rustum, Nadeem
Aghajanian, Carol
Friedman, Claire
Mcpherson, Andrew
Weigelt, Britta
Zamarin, Dmitriy
Shah, Sohrab - Abstract:
- Abstract : Objectives: Genomic instability is a hallmark of human cancer, with fundamental relevance to cancer etiology and evolution, anti-tumor immunity and therapeutic response. High-grade serous ovarian cancer (HGSOC) is an archetypal cancer of genomic instability defined by distinct mutational processes, intraperitoneal spread and tumor heterogeneity. As immunotherapies have thus far proven ineffective in HGSOC, we sought to establish the determinants of immune evasion in its natural disease history. Methods: We studied the impact of mutational processes and of spatial heterogeneity on cellular phenotypes in the tumor microenvironment (TME), using genome-based stratification of homologous recombination proficient (HRP) and deficient (HRD) disease subtypes, profiling single cell phenotypes from ~1 million cells by single cell RNA sequencing, and site-matched in situ spatial imaging of 160 tumor sites obtained from 42 treatment-naive patients. Results: Mutational processes in HRD-Dup (BRCA1 mt -like) tumors were associated with a high neoantigen burden, cell-intrinsic JAK/STAT signaling and CD8 + T cell dysfunction; HRD-Del (BRCA2 mt -like) tumors presented expanded M2-type macrophage populations; and foldback inversion (FBI, HRP) tumors were associated with cell-intrinsic TGFβ signaling, immune exclusion and predominantly naive T cells. HLA loss of heterozygosity was a common mechanism of immune escape in HRD tumors, connecting evolutionary selection with immune states.Abstract : Objectives: Genomic instability is a hallmark of human cancer, with fundamental relevance to cancer etiology and evolution, anti-tumor immunity and therapeutic response. High-grade serous ovarian cancer (HGSOC) is an archetypal cancer of genomic instability defined by distinct mutational processes, intraperitoneal spread and tumor heterogeneity. As immunotherapies have thus far proven ineffective in HGSOC, we sought to establish the determinants of immune evasion in its natural disease history. Methods: We studied the impact of mutational processes and of spatial heterogeneity on cellular phenotypes in the tumor microenvironment (TME), using genome-based stratification of homologous recombination proficient (HRP) and deficient (HRD) disease subtypes, profiling single cell phenotypes from ~1 million cells by single cell RNA sequencing, and site-matched in situ spatial imaging of 160 tumor sites obtained from 42 treatment-naive patients. Results: Mutational processes in HRD-Dup (BRCA1 mt -like) tumors were associated with a high neoantigen burden, cell-intrinsic JAK/STAT signaling and CD8 + T cell dysfunction; HRD-Del (BRCA2 mt -like) tumors presented expanded M2-type macrophage populations; and foldback inversion (FBI, HRP) tumors were associated with cell-intrinsic TGFβ signaling, immune exclusion and predominantly naive T cells. HLA loss of heterozygosity was a common mechanism of immune escape in HRD tumors, connecting evolutionary selection with immune states. Multi-region sampling also revealed substantial spatial variation, highlighting the adnexa as an 'immune-privileged' site, and suggesting that organ microenvironments can direct immune pruning in patients with widespread disease. Conclusions: Our findings yield mechanistic insights linking mutational processes in HGSOC to intra- and inter-patient variation in immune resistance, which can be leveraged to optimize future immuno-therapeutic strategies. … (more)
- Is Part Of:
- International journal of gynecological cancer. Volume 32(2022)Supplement 3
- Journal:
- International journal of gynecological cancer
- Issue:
- Volume 32(2022)Supplement 3
- Issue Display:
- Volume 32, Issue 3 (2022)
- Year:
- 2022
- Volume:
- 32
- Issue:
- 3
- Issue Sort Value:
- 2022-0032-0003-0000
- Page Start:
- A174
- Page End:
- A174
- Publication Date:
- 2022-12-04
- Subjects:
- Generative organs, Female -- Cancer -- Periodicals
616.99465 - Journal URLs:
- http://journals.lww.com/ijgc/pages/default.aspx ↗
http://www3.interscience.wiley.com/journal/118544021/toc ↗
https://ijgc.bmj.com/ ↗
http://journals.lww.com ↗ - DOI:
- 10.1136/ijgc-2022-igcs.390 ↗
- Languages:
- English
- ISSNs:
- 1048-891X
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4542.273500
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 24965.xml